These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26290198)

  • 41. Differences in physical chemistry and dissolution rate of solid particle aerosols from solution pressurised inhalers.
    Buttini F; Miozzi M; Balducci AG; Royall PG; Brambilla G; Colombo P; Bettini R; Forbes B
    Int J Pharm; 2014 Apr; 465(1-2):42-51. PubMed ID: 24491530
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dry powder inhalers for pulmonary drug delivery.
    Frijlink HW; De Boer AH
    Expert Opin Drug Deliv; 2004 Nov; 1(1):67-86. PubMed ID: 16296721
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Raman characterization and chemical imaging of biocolloidal self-assemblies, drug delivery systems, and pulmonary inhalation aerosols: a review.
    Mansour HM; Hickey AJ
    AAPS PharmSciTech; 2007 Nov; 8(4):E99. PubMed ID: 18181559
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Computational Models of Inhalation Therapy in Early Childhood: Therapeutic Aerosols in the Developing Acinus.
    Katan JT; Hofemeier P; Sznitman J
    J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):288-98. PubMed ID: 26907858
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications.
    Labiris NR; Dolovich MB
    Br J Clin Pharmacol; 2003 Dec; 56(6):600-12. PubMed ID: 14616419
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Model of the deposition of aerosol particles in the respiratory tract of the rat. II. Hygroscopic particle deposition.
    Ferron GA; Upadhyay S; Zimmermann R; Karg E
    J Aerosol Med Pulm Drug Deliv; 2013 Apr; 26(2):101-19. PubMed ID: 23550602
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The dispersion behaviour of dry powder inhalation formulations cannot be assessed at a single inhalation flow rate.
    Grasmeijer F; de Boer AH
    Int J Pharm; 2014 Apr; 465(1-2):165-8. PubMed ID: 24548720
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Electrostatic charge characteristics of jet nebulized aerosols.
    Kwok PC; Trietsch SJ; Kumon M; Chan HK
    J Aerosol Med Pulm Drug Deliv; 2010 Jun; 23(3):149-59. PubMed ID: 20500092
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Supercritical Fluid Particle Design of DPI Formulations (Review).
    Sun Y
    Curr Pharm Des; 2015; 21(19):2516-42. PubMed ID: 25876911
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Validating CFD Predictions of Pharmaceutical Aerosol Deposition with In Vivo Data.
    Tian G; Hindle M; Lee S; Longest PW
    Pharm Res; 2015 Oct; 32(10):3170-87. PubMed ID: 25944585
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Deposition, imaging, and clearance: what remains to be done?
    Scheuch G; Bennett W; Borgström L; Clark A; Dalby R; Dolovich M; Fleming J; Gehr P; Gonda I; O'Callaghan C; Taylor G; Newman S
    J Aerosol Med Pulm Drug Deliv; 2010 Dec; 23 Suppl 2():S39-57. PubMed ID: 21133799
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The formulation, chemical and physical characterisation of clarithromycin-based macrolide solution pressurised metered dose inhaler.
    Saadat A; Zhu B; Haghi M; King G; Colombo G; Young PM; Traini D
    J Pharm Pharmacol; 2014 May; 66(5):639-45. PubMed ID: 24329164
    [TBL] [Abstract][Full Text] [Related]  

  • 53. How can we bring high drug doses to the lung?
    Claus S; Weiler C; Schiewe J; Friess W
    Eur J Pharm Biopharm; 2014 Jan; 86(1):1-6. PubMed ID: 24300444
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
    Muralidharan P; Hayes D; Mansour HM
    Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Measuring The Bipolar Charge Distributions of Fine Particle Aerosol Clouds of Commercial PMDI Suspensions Using a Bipolar Next Generation Impactor (bp-NGI).
    Rowland M; Cavecchi A; Thielmann F; Kulon J; Shur J; Price R
    Pharm Res; 2018 Nov; 36(1):15. PubMed ID: 30478630
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Investigation of triboelectric charging in dry powder inhalers using electrical low pressure impactor (ELPI).
    Telko MJ; Kujanpää J; Hickey AJ
    Int J Pharm; 2007 May; 336(2):352-60. PubMed ID: 17218072
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Formation, characterization, and fate of inhaled drug nanoparticles.
    Zhang J; Wu L; Chan HK; Watanabe W
    Adv Drug Deliv Rev; 2011 May; 63(6):441-55. PubMed ID: 21118707
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optical diagnostics studies of air flow and powder fluidisation in Nexthaler®. Part II: Use of fluorescent imaging to characterise transient release of fines from a dry powder inhaler.
    Merusi C; Brambilla G; Long EJ; Hargrave GK; Versteeg HK
    Int J Pharm; 2018 Oct; 549(1-2):96-108. PubMed ID: 30017819
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Crystal Engineering: Upcoming Paradigm for Efficacious Pulmonary Drug Delivery.
    Desai PP; Mapara SS; Patravale VB
    Curr Pharm Des; 2018; 24(21):2438-2455. PubMed ID: 29773055
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discrete Modelling of Powder Dispersion in Dry Powder Inhalers - A Brief Review.
    Tong Z; Yu A; Chan HK; Yang R
    Curr Pharm Des; 2015; 21(27):3966-73. PubMed ID: 26290194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.